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Abstract
This is the second half of a two-part document updating the standard of care recommendations for spinal muscular atrophy published in 2007.
This part includes updated recommendations on pulmonary management and acute care issues, and topics that have emerged in the last few years
such as other organ involvement in the severe forms of spinal muscular atrophy and the role of medications. Ethical issues and the choice of
palliative versus supportive care are also addressed. These recommendations are becoming increasingly relevant given recent clinical trials and the
prospect that commercially available therapies will likely change the survival and natural history of this disease.
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1. Introduction
This is the second part of a two-part document aimed at
updating the standards of care recommendations published in
2007 [1]. Included here is an update of some of the topics
included in the earlier publication, such as respiratory
management, but also topics that were only described briefly in
the original publication, such as acute care, other organ
involvement and ethical issues. Recent clinical trials [2,3] and
the approval in December 2016 by the United States Food and
Drug Administration, and subsequently in May 2017 by the
European Medicine Agency, of the first drug for SMA have led
to include a review of ‘medication’ in order to provide the state
of art on the medications that have been used in the last decade,
and a brief update on the new therapeutic approaches that are
becoming available. This update also takes into consideration
how the impact of new therapies is changing the attitude of
families and physicians toward a more proactive approach,
especially in type 1 spinal muscular atrophy (SMA).As with the
first part, this update includes the results of dedicated working
groups of experts in each topic, who, after a thorough review of
the literature, used a Delphi analysis process to identify areas
where evidence could be extrapolated from the literature and
establish whether consensus could be reached among experts.
Details of the methodology used are available in the first part
and in a recent workshop report [4].
2. Pulmonary management
It is well known that spinal muscular atrophy has an impact
on the respiratory system that is dependent in large part on the
type of SMA or more precisely the severity of loss of muscle
function [5].
3. Non-sitters
3.1. Assessment
The focus of the clinical assessment should be a physical
examination (Table 1). Screening non-sitters for respiratory
failure should include assessment with pulse oximetry and
capnography (end tidal CO2 (EtCO2) or transcutaneous CO2
(TcCO2)) when awake), and using sleep study or pneumogram
with CO2 recording when there is even minimal suspicion of
hypoventilation. Data from the literature and expert opinion
supports using a sleep study to confirm when a patient has sleep
disordered breathing or respiratory failure and needs to use
non-invasive positive pressure ventilation (NIV) [6].
Clinic visits are recommended initially for every 3 months
for non-sitting patients with SMA.
3.2. Intervention
Over the last decade, the approach to treating the pulmonary
manifestations of SMA has shifted from a reactive approach, of
starting treatment to support airway clearance and ventilation
only when there is a clear indication, to a proactive approach of
introducing these therapies earlier in the disease process [7].
(Fig. 1). A respiratory therapist should be involved to initiate
and support assisted airway clearance and respiratory range of
motion therapy.
3.3. Airway clearance
Manual chest physiotherapy combined with mechanical
insufflation–exsufflation (e.g., CoughAssist® or VitalCough®)
should be the primary mode of airway clearance therapy and
should be made available to all non-sitters (Table 1). Because of
the importance of aggressive management of respiratory
illnesses [6,8–12], airway clearance techniques should be
introduced proactively in patients based on either clinical
assessment of cough effectiveness or by measuring peak cough
flow (not a routinely performed test in infants) [6]. When
initiating cough assist devices, the insufflation and exsufflation
pressures should be increased gradually to 30–40 cm H2O of
positive or negative pressure, respectively [10], or instead
increase them to the maximal tolerated pressure.
In the absence of significant parenchymal lung disease with
small airway obstruction and air trapping there is no significant
risk of pneumothorax in using the cough assist. While there is
the potential of aerophagia and gastric distention in using the
cough assist, this risk and the subsequent risk of aspiration can
be mitigated in GTube venting to prevent gastric distention.
While there are case reports suggesting the use of
mechanical insufflation or NIV to help prevent chest wall
distortion [10,13,14], there was less consensus whether this is
always a reasonable expectation and on the specifics of how to
best accomplish this (supplementary Table S1).
Oral suctioning with a mechanical suction pump and
catheter is a critical part of airway clearance in non-sitters and
should be used with any patient with an ineffective cough.
The high frequency chest wall oscillation (Vest) therapy
does not improve clearance of secretions in the setting of an
ineffective cough or improve clearance of secretions.
3.4. Ventilation
Non-invasive positive pressure ventilation (NIV) should be
used in all symptomatic infants [8–10,14,15], and in non-sitters
prior to signs of respiratory failure, to be “prepared” for
respiratory failure, prevent/minimize chest wall distortion, and
palliate dyspnea.
Continuous positive airway pressure (CPAP) should not be
used to treat chronic respiratory failure, but may be used with
caution temporarily to help maintain resting lung volume
(functional residual capacity (FRC)) in younger patients who are
unable to synchronize with the ventilator in NIV mode, and who
are not markedly hypercapnic. This applies also to weak non-
sitters. It should be recognized that CPAP may fatigue SMA
patients and could interfere with weaning from full time use.
Interface selection and fitting to the patient by an experienced
clinician is strongly recommended, as was using at least two
comfortable interfaces with different facial contact points, and
using a nasal interface initially. In non-sitters there is strong
support for initiating NIV using clinical titration with focus on
correcting gas exchange and reducing the work of breathing.
Tracheotomy ventilation is an option in selected patients in
whom NIV is insufficient or fails, or if there is no effective
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interface for providing ventilation. This should be a decision
focused individually on the clinical status, prognosis, and
quality of life based on discussion with the family.
3.5. Medications
Nebulized bronchodilators should be available if there is
suspicion for asthma. Nebulized mucolytics, 3% or 7%
hypertonic saline or dornase-α (Pulmozyme®) should not be
used long-term as there is no evidence to support its use.
Furthermore, if 3% or 7% saline is used beyond the therapeutic
need it can thin secretions of normal viscosity thereby increasing
secretion burden. Glycopyrrolate should be used with caution to
treat hypersalivation with great care to adjust the dose to attain
the proper effect, and avoid over drying of secretions, which may
contribute to the development of mucus plugs. There was no
consensus for the injection of botulinum toxin into the salivary
glands or other methods to reduce production of oral secretions.
Palivizumab should be given during RSV season as determined
by regional RSV activity through the first 24 months of life, and
influenza vaccination should be administered annually after 6
months of age. Gastroesophageal reflux should be searched for
and treated when present.
4. Sitters
4.1. Assessment
The focus of the clinical assessment should be a physical
examination supported by clinical assessment of cough function.
For sitters and standers, there is consensus that all patients able to
perform spirometry should do so during each visit.
Table 1
Pulmonary assessment, intervention and management recommendations.
Assessment Intervention Care considerations
Physical examination
Assessment of hypoventilation
(End tidal CO2)
Sleep study or pneumograms in all
symptomatic patients or to determine if a
patient needs to initiate NIV
Clinical assessment of gastroesophageal
reflux
Support airway clearance
Oral suctioning
Physiotherapy/respiratory therapy should be
implemented immediately:
Manual chest therapy
Cough insufflator/exsufflator
Assessments should be performed at least every 3
months initially, then every 6 months
Supporting airway clearance with oronasal
suctioning, physiotherapy/respiratory therapy and
cough assist is critical to all non-sitters with
ineffective cough
Non-sitters
Support ventilation with bilevel NIV in
symptomatic patients
Ventilation should be started in all symptomatic
patients. Some experts recommend using it before
documented respiratory failure to palliate dyspnea.
This should be judged on individual basis
NIV should be initiated in observing the patient
clinically for adequate gas exchange or during a
sleep study.
NIV interfaces should be fitted by skilled
physiotherapists selecting two interfaces with
different skin contact points.
Nebulized bronchodilators in patients with
asthma or a positive bronchodilator
response
Mucolytics should not be used long-term
Customary immunizations, palivizumab
through 24 months, influenza vaccination
annually after 6 months of age
Sitters Physical examination
Spirometry (when possible depending on
age and cooperation)
Sleep study or pneumograms in all patients
with even minimal suspicion of symptoms
of nocturnal hypoventilation
Assessment of gastroesophageal reflux
Support airway clearance
Physiotherapy/respiratory therapy should be
implemented immediately:
Manual chest physiotherapy
Cough insufflator/exsufflator
Assessments should be performed every 6 months
Supporting airway clearance is critical to all
patients with ineffective cough
Support ventilation with bilevel NIV in
symptomatic patients
Ventilation should be started in all symptomatic
patients. Some experts recommend using it during
acute respiratory illnesses to facilitate discharge.
NIV should be initiated during a sleep study or
observing the patient clinically for adequate gas
exchange.
NIV interfaces should be fitted by skilled
physiotherapists selecting two interfaces to
alternate skin contact points.
Nebulized bronchodilators in patients with
suspicion of asthma
Customary immunizations, annual influenza
and pneumococcal vaccination
Mucolytics should not be used long-term
Ambulant Clinical examination with review of cough
effectiveness and detailed search for signs
of nocturnal hypoventilation
Supportive care when needed
Customary immunizations, annual influenza
and pneumococcal vaccination
Evidence of weak cough or recurrent infections or
suspicion of nocturnal hypoventilation should
prompt referral to a pneumologist
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There was no clear consensus on the value of peak cough
flow measurement or when a sleep study should be performed
in the management of sitters. A sleep study should always be
performed, however, in symptomatic patients or when there is
even a minimal suspicion of nocturnal hypoventilation to
determine when a patient has sleep disordered breathing or
respiratory insufficiency and needs to use bilevel NIV [6].
Clinic visits are recommended, every 6 months for sitters.
5. Intervention
5.1. Airway clearance
Manual chest physiotherapy combined with mechanical
insufflation-exsufflation (e.g., Cough Assist® or VitalCough®)
should be made available to all patients with an ineffective
cough. It should be introduced proactively in patients using
either clinical assessment of cough effectiveness or by
measuring peak cough flow [6]. The issues related to settings
are similar to those described for non-sitters.
5.2. Ventilation
Similar to non-sitters, non-invasive positive pressure
ventilation (NIV) should be used in all symptomatic patients
[8–10,14,15]. The best approach is individualized to each
patient’s need and quality of life. A sleep study should be used
to determine when a patient has sleep disordered breathing or
respiratory failure and needs to use bilevel NIV, and to titrate
settings [6]. (Fig. 1)
As reported for non-sitters, continuous positive airway
pressure (CPAP), with rare exceptions, should not be used.
The need for tracheostomy ventilation is less frequent than
in non-sitters but in some weak sitters bilevel NIV can be
insufficient or fail. As for non-sitters this should be a decision
based on clinical status and discussion with the family and
patient, if age-appropriate.
5.3. Medications
Nebulized bronchodilators should be available if there is high
suspicion for asthma or a clear clinical improvement after
administration. Nebulized mucolytics should not be used long-
term. Annual influenza and pneumococcal immunizations
should be administered per standard pediatric recommendations
for patients with chronic neuromuscular conditions.
6. Walkers
6.1. Assessment
Most ambulant patients with SMA type 3 have normal
pulmonary function, but with a small decline noted over a
4-year span in one natural history study [5,16]. Nonetheless,
the clinical assessment of these patients should include careful
review of cough effectiveness with an upper respiratory infection,
and search for any symptoms of sleep apnea or hypoventilation
(snoring, arousals, morning headaches, daytime somnolence).
The presence of any such concerns should prompt an assessment
by a pulmonologist with consideration of pulmonary function
testing and sleep study. Pre-operative assessment is also important.
6.2. Intervention
No pro-active interventions are indicated for ambulant
patients with SMA. Supportive care should be provided when
there are specific concerns identified in the clinical assessment.
Immunizations are the same as for sitters.
6.3. Acute care management
Acute care for children and adults with SMA expands upon
the vigilant respiratory and multidisciplinary care recommended
for outpatient management. Individuals affected by SMA are
particularly vulnerable to acute respiratory decompensation,
related to community-acquired infections, aspiration, and impaired
Fig. 1. Respiratory clinical algorithm.
(REM: rapid eye movements; NREM, non-REM; FVC: forced vital capacity)
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secretion clearance [1,17,18]. Baseline diffuse muscle weakness
is often exacerbated during illness.Associated increased metabolic
demands with insensible fluid losses necessitate additional
consideration of appropriate nutritional support and avoiding
fasting [19–21]. Acute hospitalization may be required to
support those with SMA experiencing the range of routine
illnesses (e.g., viral respiratory infection, gastroenteritis with
dehydration, and appendicitis among other acute processes),
unanticipated bone fracture management, labor and delivery
for women with SMA, and scheduled surgical procedures
(e.g., gastrostomy tube placement, femoral osteotomies, and
spinal instrumentation along with other preventative strategies,
supportive interventions, or symptom management). Extensive
consideration is required, whether admission is planned or
unanticipated at the individual’s primary neuromuscular care
hospital or other institution (Table 2). The following considerations
were devised mainly for non-sitters and sitters but some
aspects may also be applied to weak ambulant type 3 children
and adults who also often present some degree of respiratory
impairment or nutritional issues and are at higher risk during
acute illness (supplementary Table S2).
6.4. Assessment and management of acute illness at home
Individualized anticipatory care plans should be developed
and include review of vital signs (e.g., oxygen desaturation
and tachycardia) and symptom parameters and prompting
escalation of care with specific recommendations for airway
clearance, ventilation, nutrition, hydration, antibiotics, and
emergency contact measures (Table 2).
Patient-specific protocols should be created based upon
community resources, emergency medical services, and
hospital capacity to provide for children and adults with SMA
and other neuromuscular conditions.
When appropriate, families should be provided with
homecare technology for monitoring respiratory function and
providing related support, such as augmented secretion clearance,
bilevel NIV to prevent hospitalization, and to optimize
status prior to presentation. This equipment, when available,
should be, brought by the family for possible use during
transport.
As part of the anticipatory care, discussions with families
about the options for both chronic and acute respiratory care
should occur early in the disease course and written
anticipatory resuscitation statements prepared with the family
should be available for any professional involved in the
transport or in the emergency room. Similarly, families should
have a list of medical needs and neuromuscular providers
including pulmonology/respirology.
Criteria for presentation to emergency care should include
severity of acute clinical signs and symptoms in relation to
capacity and limitations of homecare technology and providers.
Table 2
Acute care goals, intervention strategies and management recommendations: Home care and transportation.
Home care setting Individualized anticipatory care plans should be
developed and outline:
• airway clearance,
• ventilation,
• nutrition,
• hydration,
• antibiotics,
• emergency contact measures
Augmented secretion clearance, bilevel NIV, and oxygen supplementation
should be provided to prevent hospitalization and/or optimize status prior
to presentation
Local emergency services should be made aware of the individual’s
needs in advance.
General assessment and review of signs and
symptoms
Respiratory assessment and support should be of highest priority
independent of hospitalization indication
Criteria/thresholds for presentation to emergency
care
Criteria should include severity of clinical signs and symptoms in
relation to capacity of homecare providers (nursing and family),
limitations of homecare technology (support and monitoring)
Communication for EMS and acute care providers Families should have a summary of medical needs, list of primary
providers, care protocols, and written anticipatory resuscitation statement
available.
Community first responders
transportation
Community first responders EMS should be provided by staff with advanced cardiac life support or
equivalent certification and who have the capacity to provide noninvasive
and transtracheal ventilation for types I and II individuals.
Modality of transportation Mode of transportation between home and acute care facility should be
considered on a case-by-case basis
EMS triage Presentation to the closest facility should be considered based upon the
individual’s degree of illness, distance from a tertiary care facility,
availability of pediatric transport team, environmental considerations, and
goals of care.
Hospital level Children and young adults with SMA I or II should be hospitalized at a
tertiary care center, whether scheduled or emergent.
Personal medical equipment during transport The family should bring home equipment (e.g., NIV, cough assist device,
mask interfaces, suction machine, oximeter, gastrostomy adaptors) for use
during transport.
(NIV: non-invasive ventilation (bi-level positive air way pressure, not continuous positive airway pressure); EMS: emergency medical services, SMA: spinal
muscular atrophy).
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6.5. Transport from home to a medical facility considerations
and emergency department evaluation
Hospitalization care considerations should include site or
level of care, degree of illness, and goals of care including need
for respiratory protocols, nutrition and hydration. Non-sitters
and sitters should be triaged to tertiary care centers with SMA
expertise. Presentation to the closest facility should be
considered based upon the goals of care, distance from a
tertiary facility, availability of pediatric transport team, and
other aspects such as environmental considerations.
Engagement of the neuromuscular team providers during
acute care is critical.
Emergency medical services should be provided by certified
staff who have the capacity to provide the most appropriate
level of ventilation and cardiac and respiratory life support.
Mode of transportation between home and acute care facility
should be considered on a case-by-case basis involving the
neuromuscular team.
6.6. Medical care site/hospital capacity considerations
Respiratory assessment and support should be of highest
priority [22–25] (Table 3). Management should include
proactive measures including optimizing use of bilevel positive
airway pressure (i.e., NIV, not CPAP) respiratory support with a
backup respiratory rate (delivered via noninvasive measures,
tracheostomy, or endotracheal tube) and augmented secretion
clearance prior to empiric oxygen supplementation.
Oxygen supplementation should not be provided empirically
in the absence of NIV or without monitoring CO2 gas
exchange. Oxygen supplementation should not be withheld, but
weaned to minimal provision prior to extubation and not
employed in lieu of positive pressure ventilatory support.
The multidisciplinary team (neuromuscular and respiratory)
should be contacted to assist with acute care protocols,
involving the physician, generally the neurologist or pediatric
neurologist, who is aware of the disease course and potential
issues [26,27]. Family should be involved [28,29].
Table 3
Acute care goals, intervention strategies and management recommendations: Hospital, and sedation/anesthesia.
Hospital Goals of care Goals of care, including resuscitation status, health care proxy (when age appropriate),
indications and role of tracheostomy tubes, and other interventions, should be specified
prior to the need for acute care.
If not, the consultant teams should be engaged to facilitate discussion with the acute care
team and family.
Oxygen supplementation should not be provided empirically in the absence of bilevel NIV.
Respiratory Care Protocols Early and aggressive respiratory protocols should be implemented. Emphasis should include
proactive measures, noninvasive supports use of positive pressure and augmented secretion
clearance prior to empiric oxygen supplementation.
Augmented secretion clearance Augmented secretion clearance should be the priority during acute respiratory illness.
Respiratory support in the Emergency Room Noninvasive respiratory supports should be instituted early.
Role of the consultant team Acute care providers should contact consultant providers (e.g., neuromuscular, respiratory)
to assist with acute care protocols.
Endotracheal intubation Threshold for endotracheal intubation should be established at the outset of an admission.
Difficult airway status should be considered based upon mandibular contractures, limited
neck mobility, positioning restrictions and other factors.
Extubation criteria If pulmonary consolidation was demonstrated on radiograph, re-expansion should be
established prior to extubation. NIV should be implemented as transitional support
following extubation. Oxygen supplementation should be weaned to minimal provision prior
to extubation and not employed in lieu of positive pressure ventilation.
Sedation and
Anesthesia
Pre-anesthetic/sedation evaluation Sedation and anesthesia should be provided at a tertiary care center familiar with SMA
management.
Consultation with respiratory providers, consultant team, and an anesthesiologist familiar
with SMA should be obtained prior to sedation or general anesthesia.
Discussions should include options of noninvasive and invasive airway support.
Pre-anesthetic studies A low threshold for deferring elective/non-emergent sedation/anesthesia should be
considered during intercurrent illness across all SMA types.
Cardiology screening, polysomnograms, and nutritional assessment might be considered as
part of a pre-anesthetic evaluation
Respiratory supports (i.e., NIV and cough assist) might be introduced prior to sedation and
anesthesia to optimize preprocedural standing and for desensitization.
Sedation/anesthesia A monitored setting should be considered.
Monitoring should include capnography.
Post-sedation and anesthesia management Aggressive secretion clearance measures (cough assist when intubated and extubated)
should be integral to post-anesthetic care.
Excessive oxygen supplementation in lieu of positive pressure and extubation to NIV
should be avoided.
Analgesia provision Opiate-based analgesia should be considered as part of routine post-procedural
management. Regional analgesia might be considered for all SMA types.
(NIV: non-invasive ventilation (bi-level positive air way pressure, not continuous positive airway pressure); SMA: spinal muscular atrophy).
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As reported in the Nutritional Care Section, during acute
illness, fasting should be avoided to prevent metabolic acidosis,
hyper/hypoglycemia or fatty acid metabolism abnormalities
[20,21,30–32]. Adequate hydration and electrolyte balance are
imperative.
Attention should be paid to the risk of aspiration, when
orally feeding a weaker child during illness.
Criteria establishing the threshold for endotracheal
intubation should be established taking into account several
factors including limited neck and mandibular mobility, and
positioning restrictions and patient and family preference.
Extubation criteria and procedure should be established (see
supplementary Table S3).
There is no clear evidence to support empiric use of
antibiotics or volume resuscitation (except for sepsis management
in the general population) during acute illness or to guide viral
testing or other diagnostics. For these issues, providers should
consider presentation characteristics, the presence of indwelling
devices and history of recent surgical interventions, and recurrent
antibiotics.
Integration of physical and occupational therapy,
psychosocial services, speech-language pathologist, palliative
care services and Endocrinology consultants can contribute to
other aspects of care such as skin care or bone fracture risk.
6.7. Hospital discharge considerations
Discharge planning should begin shortly after admission to
identify goals with the patient/family, inpatient team, and
primary care providers. Planning should consider threshold for
discharge, need to augment outpatient services, follow-up care,
and indications for urgent re-hospitalization. Threshold for
discharge based on medical status will depend on the comfort
and skill of family and outpatient medical care team.
6.8. Preprocedural screening [33], anesthesia/sedation
consideration [34,35] and pain management
Polysomnograms and nutritional assessment may be
considered as part of a pre-anesthetic evaluation. Cardiology
screening is not recommended, unless there is a concern for
cardiac dysfunction in older individuals or conditions unrelated
to SMA. Difficult airway status should be considered based
upon mandibular contractures, limited neck mobility,
positioning restrictions and other factors. A low threshold for
deferring elective/non-emergent sedation/anesthesia should be
considered during intercurrent illness across all SMA types.
Opiate-based analgesia should be considered as part of routine
post-procedural management with anticipation of providing
appropriate NIV and cough assistance.
Regional analgesia may be considered for all SMA types
and may allow for lower amounts of systemic analgesics with
subsequent effects on respiratory drive and intestinal motility.
Practical consideration must be taken into account when evaluating
for epidural catheter placement in context of pre-existing
scoliosis. Monitoring during procedural sedation and anesthesia
should include capnography to complement oximetry, as apneic
or hypopneic oxygenation should be avoided.
Additional recommendations not addressed in the Delphi
survey include consideration of delivery of novel gene-targeted
therapies and other interventions for individuals with SMA.
For example, provision of repeated intrathecal drug therapies
such as recently approved antisense oligonucleotides will require
extensive planning for developmentally appropriate and safe
care, including procedural sedation, interventional radiology
support, and potential orthopedic considerations. The anticipated
emergence of gene replacement with viral vectors and other
disease/symptom modifying agents may also require extensive
acute care supports. Understanding that the natural history of
this condition and recognized phenotypes will be altered should
prompt all providers (acute, chronic, hospital-based, or
community) to engage accordingly in informed discussions
and adjustment of the acute care paradigm.
7. Medication, supplements and immunizations
Until recently no drug treatment had proved to be able to
influence the disease course of SMA. A Cochrane review
published in 2012 reported six randomized placebo-controlled
trials on treatment for SMA using creatine, phenylbutyrate,
gabapentin, thyrotropin-releasing hormone, hydroxyurea and
combination therapy with valproate and acetyl-L-carnitine
[36,37]. None of these studies showed statistically significant
effects on the outcome measures in participants with SMA
types 2 and 3. Others have reported using other possible
therapeutic approaches, such as albuterol, a beta-adrenergic
agonist that showed promising functional improvements in
open label studies [38,39].
Despite the lack of evidence from randomized placebo-
controlled trials, some of these drugs, especially albuterol, are
often used in some countries in clinical practice in sitters and
ambulant patients.
Antibiotics or medications/supplements for bone health,
such as vitamin D and calcium and bisphosphonate, or drugs
for gastroesophageal reflux, were recommended with the
exception of vitamin D, rarely used prophylactically, and
mainly used if needed/deficient. These are discussed in the
sections dedicated to bone health and nutrition.
Annual influenza and pneumococcal immunizations, as
reported in the pulmonary section, were strongly recommended.
At the time the consensus process was completed, none of
the drugs involved in clinical trial had completed the regulatory
process and were commercially available. Nusinersen
(Spinraza™), an antisense oligonucleotide that had completed
phase 3 clinical trials in both type 1 and type 2 SMA
[3,40,41], received recent approval both by the United States
Food and DrugAdministration and by the Agency for Medicines
Agency in Europe for the treatment of all SMA types and has
become commercially available in several countries. While the
early patient and family clinical outcomes have been very
favorable, because nusinersen is intrathecally administered,
there is a required institutional infrastructure to provide
administration and post-procedural monitoring in a reliable
way. In addition the cost of the medication has made long term
insurance company approval uncertain.
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Olesoxime, a neuroprotective drug, has completed a phase 3
trial in patients with type 2 and 3 SMA, but the primary
endpoint was not met. Secondary endpoints and sensitivity
analyses indicate that olesoxime might maintain motor function
in patients with SMA [42]. Other approaches, such as small
molecules aiming to increase SMN protein level or SMN1 gene
replacement using viral vector, are also being used in clinical
trials with promising preliminary results [43] and in the next
few years the scenario is likely to rapidly change.
8. Other organ system involvement
SMA is primarily a motor neuron disease but the deficient
SMN protein is ubiquitously expressed in all cells throughout
fetal and post-natal development [44–46]. Therefore, there is
ongoing discussion as to what extent other tissues might be
affected in patients with SMA. Several animal models and
some case reports or small case series report involvement of
other organ systems, such as peripheral nerve, brain, muscle,
heart, vasculature, and pancreas (for review see [47–50]).While
the involvement of other tissues might have implications for
therapeutic approaches, only a minority of patients with SMA
show clear clinical manifestation of other organ involvement.
Hemodynamically relevant cardiac defects have been
reported in very severely affected infants with SMA type 1.
Recent reviews of the literature [50,51] identified a number of
cases with congenital heart defects such as atrial or ventricular
septal defects. All of these patients showed the severe neonatal
onset, also indicated as type 0, with respiratory distress at birth.
They all had only a single copy of SMN2 [51]. In long-term
survivors with type 1 SMA receiving ventilatory support, 15 of
63 patients (24%) had severe, symptomatic bradycardia,
suggesting a possible concomitant autonomic dysfunction [52].
Cardiac involvement in contrast is much less frequent in
types 2 and 3 SMA. There are some reports of heart rate
abnormalities in type 3 SMA [53,54]. Recent studies performed
in types 2 and 3 SMA, suggested that there is no need for
regular cardiac surveillance in type 2 and type 3 patients as it is
highly unlikely that these patients will develop obvious clinical,
ECG or echocardiographic signs of cardiomyopathy [33,55].
As reported in the part on nutritional care, occasional cases
of pancreatic dysfunction including diabetes and alterations in
glucose metabolism have been reported in SMA patients [56].
Hyperleptinemia has been identified in SMA patients with
types 1, 2 and 3 [57]. Mitochondrial dysfunction has been
described in patients and human neuronal cell lines [21,58,59].
There was consensus among the experts that specific
surveillance testing for other organ involvement should
generally be based on clinical symptoms and is thus not
necessary in most patients. Possible exceptions are the
exclusion of cardiac defects in severely affected infants with
SMA type 1 and monitoring of glucose metabolism in all types
of SMA. Despite immobilization of many patients with SMA
prophylactic anticoagulation is not deemed necessary in the
absence of additional risk factors.
As intrathecal administration of nusinersen principally targets
motor neurons [40], concerns have arisen that other non-central
nervous system tissues may subsequently demonstrate symptoms
or signs of dysfunction due to deficiency of SMN protein.
Motor impairment may be alleviated while other symptoms
arise. It is recommended that patients treated with nusinersen
be monitored for these potential systemic concerns.
9. Ethical considerations
The application of palliative care along with its attendant
ethical challenges was the focus of an international
interdisciplinary group that included clinicians, bioethics
researchers, parents and patient representatives, and pediatric
palliative care specialists.
The previous version of the standards of care guidelines [1]
highlighted the lack of consensus and the controversies on
palliative versus interventional approaches. In the absence of
therapy a number of families perceived the interventional
approach, especially tracheostomy, as placing quality of life in
conflict with duration of life, prolonging suffering rather than
relieving the burden of disease [26,52,60,61]. The previous
committee reached consensus that while there was no moral
imperative to any therapy, there was a deep responsibility to
present care options in a fair and balanced manner, providing
accurate information that the choice for palliative or interventional
supportive care was not an exclusive binary choice.
The update of the literature review provided little additional
hard evidence and no consensus regarding standards of
palliative care as applied to SMA [62–65]. The working group
was, therefore, still unable to establish a consensus for palliative
care and could only acknowledge the substantive ethical issues
that must attend care decisions in the context of SMA, now also
in the light of the most recent therapeutic approaches. The
group identified 3 key areas for future analysis; 1) The concept
of palliative care as applied to SMA, 2) Patient management
and decision-making, 3) Managing expectations.
Although the concept of palliative care has been defined and
re-interpreted many times there is a need to regard this as an
ongoing reflexive process especially when applied to contexts
like SMA that are not static [66]. SMA in all of its degrees of
severity does not fit a model of a condition with a relentlessly
ingravescent course [67,68]. The recent availability of new
therapies has created substantial reasons to hope for changes in
prognosis, but several issues are in need of further clarification
before a move to a standard for palliative care in SMA can be
achieved [40,41], including the need to address the meaning of
palliative care for the SMA community. Despite recent trends
that have emphasized the role of palliative care to focus upon
improving quality of life, with a point of entry well ‘upstream’
within the disease trajectory, there is still an association of
palliative care with end of life care. There is therefore a need to
support a change of culture, which sees palliative care as having
a role alongside the treatment of chronic debilitating conditions
that have a long prognosis. A key challenge is thus to dismiss
the dichotomous model, which sets active treatment against
palliative care in favor of a model of complementarity. Ethical
challenges will doubtless still persist, requiring both clinical
evidence and good judgment to manage. One such concern is
the challenge of managing the burden of care when the
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‘therapeutic ratio’ between side-effects and benefits must be
balanced. Second is managing the phases of transition across
the disease trajectory points at which advancing disease signals
a transition in favor of palliative care and the cessation of
life-extending treatments [69]. The challenge of managing
expectations in this fluid context, especially where expectations
are shaded by many conflicting opinions, adds further
complexity to the task of establishing a standard of care.
Resource limitations and cultural differences need also to be
considered especially as variable access to resources across the
globe will mean that inequalities are inevitable.
New issues about the choice of palliative care in patients
enrolled in clinical trials are also emerging [70]. A recent
survey among physician investigators, clinical evaluators, and
study coordinators from different countries endorsed the
concept that having a predefined degree of nutritional and
ventilation support was warranted in this context.
10. Conclusions
Spinal muscular atrophy presents with a diverse range of
phenotypes of motor impairment and related comorbidities.
Effective and efficient management of the patient with SMA
requires coordination of multiple clinical specialists to address
both current concerns and anticipated ones. These updated
standard of care considerations have been developed to provide
current expert opinion on necessary care and, where appropriate,
optimal management. When reviewing the results, we were
surprised by the discrepancy between the literature and the
Delphi analysis. Although many advances in multiple aspects
of care have been made, and these had a tremendous impact on
survival, onset and severity of complications, the literature
reporting evidence was scanty. Very few studies provided a
level of evidence based on an appropriate design and most
papers reported clinical observations and small series. In
contrast, despite the paucity of evidence based recommendations,
for each topic there was a large expert consensus on many
components of SMA care. For many aspects, such as the
introduction of early spinal surgery and of cough machine
support, most, and often all the experts were convinced of the
impact of these recommendations on changing natural history.
In these cases it was felt that although large randomized
studies would have been preferable to assess more systematically
their efficacy, the impact on natural history before and after
their introduction was sufficient to recommend their inclusion
in common practice. While this lack of evidence based papers
makes it difficult to obtain an accurate estimate of the level of
efficacy of individual aspects of care, the unequivocal and
recent improvements in survival in type 1 and in the onset of
progression in all SMA types validate the impact, collectively,
of implementing these interventions.
The ultimate goal of these guidelines is to strive continually
in improving quality of life and reducing burden of disease for
these patients.While many of these considerations are technology
driven, they all begin with a focus on a patient’s clinical
symptoms and signs and related risk factors. Recommendations
are now based upon the current functional status of the patient:
non-sitter, sitter and walker. Patient and parental autonomy and
ethical dimensions must be respected. These guidelines should
thus be applied with attention to individual patient concerns
and complexities rather than as strict doctrine. Individual
probative issues to consider include patient age, general medical
status and extent of supportive care, local availability of
clinical expertise, extent of health care provisions, and new
treatment options. With the emergence of the first approved
medication for treatment of patients with SMA, it is particularly
important to meld optimal care with treatments that fundamentally
alter the natural history of the disease. This effort identified
questions that remain in many areas of supportive care for
patients with SMA and will prompt future research. Further
research is also needed on other aspects, such as psychiatric
and emotional health, or on other aspects related to optimization
of daily functioning. As the great majority of the aspects of
care are related to the most severe phenotypes that have
pediatric onset, further work is also needed to address issues
related to the older population, including teenagers and adults.
Further work is also needed to identify new models to support
families and physicians to improve local care and reduce the
number of visits and admissions to tertiary care centers.
Acknowledgements
The authors thank the European Neuromuscular Consortium
(ENMC), TREAT-NMD, SMA Europe, SMA support UK,
SMA Foundation, Cure SMA and the Italian Telethon for their
support.
Appendix: Supplementary material
Supplementary data to this article can be found online at
doi:10.1016/j.nmd.2017.11.004.
References
[1] Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al.
Consensus statement for standard of care in spinal muscular atrophy. J
Child Neurol 2007;22(8):1027–49.
[2] Kissel JT, Elsheikh B, King WM, Freimer M, Scott CB, Kolb SJ, et al.
SMA valiant trial: a prospective, double-blind, placebo-controlled trial of
valproic acid in ambulatory adults with spinal muscular atrophy. Muscle
Nerve 2014;49(2):187–92.
[3] Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J,
et al. Nusinersen versus sham control in infantile-onset spinal muscular
atrophy. N Engl J Med 2017;377:1723–32.
[4] Finkel RS, Sejersen T, Mercuri E, Group ESWS. 218th ENMC
International Workshop: revisiting the consensus on standards of care in
SMA Naarden, The Netherlands, 19–21 February 2016. Neuromusc
Disord 2017;27:596–605.
[5] Samaha FJ, Buncher CR, Russman BS, White ML, Iannaccone ST,
Barker L, et al. Pulmonary function in spinal muscular atrophy. J Child
Neurol 1994;9(3):326–9.
[6] Hull J, Aniapravan R, Chan E, Chatwin M, Forton J, Gallagher J, et al.
British Thoracic Society guideline for respiratory management of children
with neuromuscular weakness. Thorax 2012;67(Suppl. 1):1–40.
[7] Lemoine TJ, Swoboda KJ, Bratton SL, Holubkov R, Mundorff M,
Srivastava R. Spinal muscular atrophy type 1: are proactive respiratory
interventions associated with longer survival? Pediatr Critical Care Med
2012;13:e161–5.
[8] Bach JR, Baird JS, Plosky D, Navado J, Weaver B. Spinal muscular
atrophy type 1: management and outcomes. Pediatr Pulmonol
2002;34:16–22.
205R.S. Finkel et al. /Neuromuscular Disorders 28 (2018) 197–207
[9] Bach JR, Saltstein K, Sinquee D, Weaver B, Komaroff E. Long-term
survival in Werdnig Hoffmann disease. Am J Phys Med Rehabil
2007;86:339–45.
[10] Schroth MK. Special considerations in the respiratory management of
spinal muscular atrophy. Pediatrics 2009;(Suppl. 4):S245–9.
[11] Gregoretti C, Ottonello G, Chiarini Testa MB, Mastella C, Ravà L,
Bignamini E, et al. Survival of patients with spinal muscular atrophy type
1. Pediatrics 2013;131:e1509–14.
[12] Chiarini Testa MB, Paglietti MG, Pavone M, Schiavino A, Pedace C,
Cutrera R. Respiratory problems in spinal muscular atrophy in the
paediatric age group. Paediatr Child Health 2009;34:S123–6.
[13] Bach JR, Bianchi C. Prevention of pectus excavatum for children
with spinal muscular atrophy type 1. Am J Phys Med Rehabil 2003;82:
815–19.
[14] Ward S, Chatwin M, Heather S, Simonds AK. Randomised controlled trial
of non-invasive ventilation (NIV) for nocturnal hypoventilation in
neuromuscular and chest wall disease patients with daytime normocapnia.
Thorax 2005;60:1019–24.
[15] Petrone A, Pavone M, Testa MBC, Petreschi F, Bertini E, Cutrera R.
Noninvasive ventilation in children with spinal muscular atrophy types 1
and 2. Am J Phys Med Rehabil 2007;86:216–21.
[16] Kaufmann P, McDermott MP, Darras BT, Finkel RS, Sproule DM, Kang
PB, et al. Prospective cohort study of spinal muscular atrophy types 2 and
3. Neurology 2012;79:1889–97.
[17] Hull J, Aniapravan R, Chan E, Chatwin M, Forton J, Gallagher J, et al.
British Thoracic Society guideline for respiratory management of children
with neuromuscular weakness. Thorax 2012;67(Suppl. 1):i1–40.
[18] Sansone VA, Racca F, Ottonello G, Vianello A, Berardinelli A,
Crescimanno G, et al. 1st Italian SMA Family Association Consensus
Meeting: management and recommendations for respiratory involvement
in spinal muscular atrophy (SMA) types I-III, Rome, Italy, 30–31 January
2015. Neuromusc Disord 2015;25:979–89.
[19] Zolkipli Z, Sherlock M, Biggar WD, Taylor G, Hutchison JS, Peliowski A,
et al. Abnormal fatty acid metabolism in spinal muscular atrophy may
predispose to perioperative risks. Eur J Paediatr Neurol 2012;16:549–
53.
[20] Orngreen MC, Zacho M, Hebert A, Laub M, Vissing J. Patients with
severe muscle wasting are prone to develop hypoglycemia during fasting.
Neurology 2003;61:997–1000.
[21] Crawford TO, Sladky JT, Hurko O, Besner-Johnston A, Kelley RI.
Abnormal fatty acid metabolism in childhood spinal muscular atrophy.
Ann Neurol 1999;45:337–43.
[22] Khirani S, Bersanini C, Aubertin G, Bachy M, Vialle R, Fauroux B.
Non-invasive positive pressure ventilation to facilitate the post-operative
respiratory outcome of spine surgery in neuromuscular children. Eur
Spine J 2014;23(Suppl. 4):S406–11.
[23] Ottonello G, Mastella C, Franceschi A, Bosticco D, Wolfler A, Pedemonte
M, et al. Spinal muscular atrophy type 1: avoidance of hospitalization by
respiratory muscle support. Am J Phys Med Rehabil 2011;90:895–900.
[24] Bach JR, Niranjan V, Weaver B. Spinal muscular atrophy type 1: a
noninvasive respiratory management approach. Chest 2000;117:1100–5.
[25] Vianello A, Corrado A, Arcaro G, Gallan F, Ori C, Minuzzo M, et al.
Mechanical insufflation-exsufflation improves outcomes for neuromuscular
disease patients with respiratory tract infections. Am J Phys Med
Rehabil 2005;84:83–8.
[26] Hardart MK, Burns JP, Truog RD. Respiratory support in spinal muscular
atrophy type I: a survey of physician practices and attitudes. Pediatrics
2002;110:e24.
[27] Geevasinga N, Ryan MM. Physician attitudes towards ventilatory support
for spinal muscular atrophy type 1 in Australasia. J Paediatr Child Health
2007;43:790–4.
[28] Graham RJ, Pemstein DM, Curley MA. Experiencing the pediatric
intensive care unit: perspective from parents of children with severe
antecedent disabilities. Crit Care Med 2009;37:2064–70.
[29] Ottonello G, Mastella C, Franceschi A, Lampugnani E, Moscatelli A,
Punch F, et al. Parental role in the Intensive Care Unit for children
affected by Werdnig Hoffmann disease. Minerva Pediatr 2010;62:
147–51.
[30] Davis RH, Godshall BJ, Seffrood E, Marcus M, LaSalle BA, Wong B,
et al. Nutritional practices at a glance: spinal muscular atrophy type I
nutrition survey findings. J Child Neurol 2014;29:1467–72.
[31] Tein I, Sloane AE, Donner EJ, Lehotay DC, Millington DS, Kelley RI.
Fatty acid oxidation abnormalities in childhood-onset spinal muscular
atrophy: primary or secondary defect(s). Pediatr Neurol 1995;12:21–30.
[32] Bruce AK, Jacobsen E, Dossing H, Kondrup J. Hypoglycaemia in spinal
muscular atrophy. Lancet 1995;346:609–10.
[33] Bianco F, Pane M, D’Amico A, Messina S, Delogu AB, Soraru G, et al.
Cardiac function in types II and III spinal muscular atrophy: should we
change standards of care? Neuropediatrics 2015;46:33–6.
[34] Norton JA, Roy FD, Mahood JK. Preservation of motor evoked potentials
under anesthesia in children with spinal muscular atrophy type II
undergoing spinal deformity surgery. J Clin Neurophysiol 2013;30:
382–5.
[35] Graham RJ, Athiraman U, Laubach AE, Sethna NF. Anesthesia and
perioperative medical management of children with spinal muscular
atrophy. Paediatr Anaesth 2009;19:1054–63.
[36] BosboomW, Vrancken AF, van den Berg LH, Wokke JH, Iannaccone ST.
Drug treatment for spinal muscular atrophy types II and III. Cochrane
Database Syst Rev 2009;(7):CD006282.
[37] Wadman RI, Bosboom WM, van der Pol WL, van den Berg LH, Wokke
JH, Iannaccone ST, et al. Drug treatment for spinal muscular atrophy type
I. Cochrane Database Syst Rev 2012;(4):CD006281.
[38] Kinali M, Mercuri E, Main M, De Biasia F, Karatza A, Higgins R, et al.
Pilot trial of albuterol in spinal muscular atrophy. Neurology
2002;59:609–10.
[39] Pane M, Staccioli S, Messina S, D’Amico A, Pelliccioni M, Mazzone ES,
et al. Daily salbutamol in young patients with SMA type II. Neuromusc
Disord 2008;18:536–40.
[40] Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De
Vivo DC, et al. Results from a phase 1 study of nusinersen
(ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology
2016;86:890–7.
[41] Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al.
Treatment of infantile-onset spinal muscular atrophy with nusinersen:
a phase 2, open-label, dose-escalation study. Lancet 2016;388:3017–
26.
[42] Bertini E, Mercuri E, Muntoni F, Kirschner J, Reid C, Lusakowska A,
et al. Safety and efficacy of olesoxime in patients with type 2 or
non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind
placebo controlled phase 2 trial. Lancet Neurol 2017;16(7):513–22.
[43] Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior
TW, et al. Single-dose gene-replacement therapy for spinal muscular
atrophy. N Engl J Med 2017;377:1713–22.
[44] Coovert DD, Le TT, McAndrew PE, Strasswimmer J, Crawford TO,
Mendell JR, et al. The survival motor neuron protein in spinal muscular
atrophy. Hum Mol Genet 1997;6:1205–14.
[45] Tizzano EF, Cabot C, Baiget M. Cell-specific survival motor neuron gene
expression during human development of the central nervous system:
implications for the pathogenesis of spinal muscular atrophy. Am J Pathol
1998;153:355–61.
[46] Pellizzoni L, Kataoka N, Charroux B, Dreyfuss G. A novel function for
SMN, the spinal muscular atrophy disease gene product, in pre-mRNA
splicing. Cell 1998;95:615–24.
[47] Hamilton G, Gillingwater TH. Spinal muscular atrophy: going beyond the
motor neuron. Trends Mol Med 2013;19:40–50.
[48] Shababi M, Lorson CL, Rudnik-Schoneborn SS. Spinal muscular
atrophy: a motor neuron disorder or a multi-organ disease? J Anat
2014;224:15–28.
[49] Shababi M, Habibi J, Yang HT, Vale SM, Sewell WA, Lorson CL. Cardiac
defects contribute to the pathology of spinal muscular atrophy models.
Hum Mol Genet 2010;19:4059–71.
[50] Lorson CL, Rindt H, Shababi M. Spinal muscular atrophy: mechanisms
and therapeutic strategies. Hum Mol Genet 2010;19:R111–18.
[51] Rudnik-Schoneborn S, Heller R, Berg C, Betzler C, Grimm T, Eggermann
T, et al. Congenital heart disease is a feature of severe infantile spinal
muscular atrophy. J Med Genet 2008;45:635–8.
206 R.S. Finkel et al. /Neuromuscular Disorders 28 (2018) 197–207
[52] Bach JR. Medical considerations of long-term survival of
Werdnig-Hoffmann disease. Am J Phys Med Rehabil 2007;86:349–55.
[53] Takahashi N, Shimada T, Ishibashi Y, Sugamori T, Hirano Y, Oyake N,
et al. Cardiac involvement in Kugelberg-Welander disease: a case report
and review. Am J Med Sci 2006;332:354–6.
[54] Elkohen M, Vaksmann G, Elkohen MR, Francart C, Foucher C, Rey C.
[Cardiac involvement in Kugelberg-Welander disease. A prospective
study of 8 cases]. Arch Mal Coeur Vaiss 1996;89:611–17.
[55] Palladino A, Passamano L, Taglia A, D’Ambrosio P, Scutifero M, Cecio
MR, et al. Cardiac involvement in patients with spinal muscular atrophies.
Acta Myol 2011;30:175–8.
[56] Bowerman M, Swoboda KJ, Michalski JP, Wang GS, Reeks C, Beauvais
A, et al. Glucose metabolism and pancreatic defects in spinal muscular
atrophy. Ann Neurol 2012;72:256–68.
[57] Kolbel H, Hauffa BP, Wudy SA, Bouikidis A, Della Marina A, Schara U.
Hyperleptinemia in children with autosomal recessive spinal muscular
atrophy type I-III. PLoS ONE 2017;12:e0173144.
[58] Acsadi G, Lee I, Li X, Khaidakov M, Pecinova A, Parker GC, et al.
Mitochondrial dysfunction in a neural cell model of spinal muscular
atrophy. J Neurosci Res 2009;87:2748–56.
[59] Xu CC, Denton KR, Wang ZB, Zhang X, Li XJ. Abnormal mitochondrial
transport and morphology as early pathological changes in human models
of spinal muscular atrophy. Dis Model Mech 2016;9:39–49.
[60] Bach JR. Threats to “informed” advance directives for the
severely physically challenged? Arch Phys Med Rehabil 2003;84:
S23–8.
[61] Sakakihara Y. Ethical attitudes of Japanese physicians regarding
life-sustaining treatment for children with severe neurological disabilities.
Brain Dev 2000;22:113–17.
[62] Roper H, Quinlivan R, Workshop P. Implementation of “the consensus
statement for the standard of care in spinal muscular atrophy” when
applied to infants with severe type 1 SMA in the UK. Arch Dis Child
2010;95:845–9.
[63] Cuisset JM, Estournet B, French Ministry of Health. Recommendations
for the diagnosis and management of typical childhood spinal muscular
atrophy. Rev Neurol (Paris) 2012;168:902–9.
[64] Mitchell I. Spinal muscular atrophy type 1: what are the ethics and
practicality of respiratory support? Paediatr Resp Reviews 2006;7(Suppl.
1):S210–11.
[65] Garcia-Salido A, de Paso-Mora MG, Monleon-Luque M, Martino-Alba
R. Palliative care in children with spinal muscular atrophy type I: what do
they need? Palliat Support Car 2015;13:313–17.
[66] Woods S. Clark D, editor. Death’s dominion: ethics at the end of life.
Facing death series. Open University Press; 2007.
[67] Chung BH, Wong VC, Ip P. Spinal muscular atrophy: survival pattern and
functional status. Pediatrics 2004;114:e548–53.
[68] Farrar MA, Vucic S, Johnston HM, du Sart D, Kiernan MC.
Pathophysiological insights derived by natural history and motor function
of spinal muscular atrophy. J Pediatr 2013;162:155–9.
[69] Lovgren M, Sejersen T, Kreicbergs U. Parents’ experiences and wishes at
end of life in children with spinal muscular atrophy types I and II. J Pediatr
2016;175:201–5.
[70] Finkel RS, Bishop KM, Nelson RM. Spinal muscular atrophy type I: is it
ethical to standardize supportive care intervention in clinical trials? J
Child Neurol 2017;32:155–60.
[71] American Academy of Pediatrics Steering Committee on Quality I,
Management. Classifying recommendations for clinical practice
guidelines. Pediatrics 2004;114:874–7.
207R.S. Finkel et al. /Neuromuscular Disorders 28 (2018) 197–207
